Nifuromed 220 mg / 5 ml

Pharmaceutical form: Oral suspension

Composition: 5 ml of oral suspension contain: active ingredient nifuroxazide 220 mg.
Excipinets: Sucrose, xanthan, methylparahydroxybenzoate, propylparahydroxybenzoate, banana flavor.

Pharmacological group: Intestinal anti-microbial and anti-inflammatory drugs.

Pharmacological properties:
An antimicrobial agent with a wide spectrum of activity, a 5-nitrofuran derivative. It blocs dehydrogenases activity and inhibits respiratory chains, tricarboxylic acid cycle and some other biochemical processes in a microbial cell. Lyses microbial cell membrane, decreases toxins production by microorganisms. Activates the immune system: increases phagocytosis and complement titer. It is effective against Gram-positive microorganisms (Staphylococcus aureus, Streptococcus pyogenes, Clostridium perfringens), and Gram-negative microorganisms (Escherihia coli, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter spp., Vibrio cholerae, Campylobacter jejuni, Edwarsiella, Citrobacter, Yersinia enterocolitica). Does not disturb the balance of intestinal microflora. In acute bacterial diarrhea, it restores intestinal eubiosis. In infections with enterotropic viruses, prevents the development of bacterial superinfection. After oral administration it is practically not absorbed from gastrointestinal tract forming a high concentration of the active substance in the intestine. Due to such pharmacokinetic features, the drug exhibits an exclusively enteral antiseptic effect, does not have systemic antibacterial activity, and does not cause general toxic effects; excreted from the body with feces. The drug does not affect the clinical and biochemical parameters of the blood test.

Indications:
- Treatment of diarrhea caused by drug-sensitive infections;
- Combined treatment of chronic colitis and enterocolitis.

Contraindications:
The drug is contraindicated in case of hypersensitivity to any component, as well as in case of allergy to 5-nitrofuran derivatives. Children age up to 2 months, premature.

Posology and method administration
The drug is administered orally. Shake the bottle thoroughly before use until a homogeneous suspension is obtained.
Doses for children:

- 2 to 6 months - 2.5 ml, 2 times a day,
- From 6 months to 6 years of age - 5 ml, 3 times a day,
- children over 6 years of age - 5 ml, 4 times a day,
- Doses for adults - 5 ml, 4 times a day.

2.5 ml of Nifuromed contains 110 mg of Nifuroxazide.
5 ml of Nifuromed contains 220 mg of Nifuroxazide.
The drug is recommended to be taken at regular intervals, regardless of the meal. Duration of treatment is 5-7 days.

Side effects:
Nifuromed is well tolerated, practically does not show side effects, only occasionally there may be temporary pain in the abdomen, nausea, increased diarrhea. These symptoms do not require suspension of treatment with the drug. In cases of individual hypersensitivity to the drug (shortness of breath, skin rash, itching) is possible, which requires discontinuation of the drug.

Warnings and precautions:
The drug is not prescribed as monotherapy for the treatment of intestinal infections complicated by septicemia. If there are symptoms of dehydration, in combination with treatment, it is necessary to carry out rehydration therapy (for adults - about 2 liters of fluid per day). The drug is used with the obligatory observance of a diet, excluding juices, raw vegetables and fruits, as well as spicy and hard-to-digest foods. Before prescribing a suspension to infants, it is necessary to exclude a congenital deficiency of enzymes that break down sucrose.

Pregnancy and period of breastfeeding
There are no clinical data regarding on the fetus the use of drug during pregnancy.
If necessary, with caution, the drug can be prescribed to pregnant women and period of breastfeeding.

Packaging:
100 ml Glass Bottles with dosage cup and Patient Information Leaflet completed in a Paperboard box.

Shelf life:
3 years. Open containers should be used within 14 days.

Storage conditions:
In a dry place, out of reach of children, at a temperature below 25°C.

Regulatory status:

Prescription only.